dr donna h ryan glp-1 H. Ryan, MD Clinical Trials Archives - ADA

GLP-1s are shaking up the playbook and giving pharma companies a whole new set of moves to master

Compounded semaglutide and Ozempic contain the same active ingredient but differ significantly in price, insurance requirements, and access pathways

While oral formulations offer the convenience of a pill compared to traditional injections, this shift also raises important compliance considerations

In 2024, researchers published a study demonstrating programmable microneedle technology capable of sustained semaglutide delivery, highlighting the potential of transdermal GLP-1 administration

Digital weight loss company Noom has entered the evolving GLP-1 medication landscape with the launch of its Noom Microdose GLP-1Rx Program, offering members personalized microdoses of GLP-1 medications combined with behavioral coaching and clinical support

Formulated with Berberine, Green Tea EGCG, and Capsaicinoids to support GLP-1 activity and metabolic health*